In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Inc.

http://www.pfizer.com

Latest From Pfizer Inc.

Pepaxto Adcom Saw Public Airing Of Unusual Level Of Discord Between US FDA, Oncopeptides

The four-hour virtual public meeting featured "incompatible" views of the FDA and sponsor on the OCEAN data, not to mention signs of impatience and resentment, with each side criticizing the positions of the other over the safety and efficacy of the multiple myeloma drug.

Advisory Committees Post Market Regulation & Studies

Deal Watch: Bristol Accesses Tech Platforms From SyntheX, Autolus

Pharma will partner with SyntheX on targeted protein degradation, with Autolus on cell therapy safety. Novo Nordisk gets rights to Ventus’s lead compound in NASH and chronic kidney disease.

Deal Watch Business Strategies

Pfizer Reveals Secret Digital Sauce To Cut Trial Duration, MLR Review Times

How do you send 90,000 employees home and still bring a COVID-19 vaccine to market in record time? Pfizer showed the way and at a recent virtual event, senior vice-president Robert Brown revealed how the "secret sauce" of digitalization continues to help cut medical legal review times, crunch clinical trial duration and reduce service interruptions.

Commercial Business Strategies

Yakult's Japan Duvelisib Decision Casts New Shadow Over Shrinking Pharma Ops

Yakult’s decision to pull an approval application for duvelisib in Japan came shortly after a FDA advisory committee said it would re-evaluate the safety and efficacy of the PI3K inhibitor four years since its approval. The developments cast a new shadow over Yakult’s already-suffering pharmaceutical business.

Commercial Japan
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Agouron Pharmaceuticals
    • Alpharma Pharmaceuticals LLC
    • American Home Products
    • Amplyx Pharmaceuticals, Inc.
    • Anacor Pharmaceuticals, Inc.
    • Array BioPharma, Inc. (ARRY)
    • Arixa Pharmaceuticals, Inc. Bamboo Therapeutics, Inc.
    • Bioren, Inc,
    • Coley Pharmaceutical Group, Inc.
    • CovX Pharmaceuticals, Inc
    • C.P. Pharmaceuticals International C.V.
    • Encysive Pharmaceuticals
    • Excaliard
    • FoldRx Pharmaceuticals, Inc.
    • Ferrosan Consumer Health
    • GD Searle
    • Hisun-Pfizer Pharmaceuticals Co., Ltd.
    • Hospira, Inc.
    • Icagen, Inc.
    • Idun Pharmaceuticals, Inc.
    • InnoPharma
    • Javelin Pharmaceuticals, Inc.
    • King Pharmaceuticals, Inc.
    • Lederle Laboratories
    • Mayne Pharma Limited
    • Meridica Limited
    • Neusentis
    • Parke-Davis
    • Pharmacia
    • Pharmacia and Upjohn Co.
    • PHT Pharma S.r.l.
    • Powdermed
    • Redvax GmbH
    • ReViral Ltd.
    • Serenex
    • Strato Medical Corp.
    • SUGEN
    • Texas Biothechnology Corporation
    • Thiakis Limited
    • Vicuron Pharmaceuticals
    • ViiV Healthcare
    • Warner-Lambert
    • Wyeth
    • Wyeth-Ayerst Laboratories, Inc.
    • Treerly Health Co., Ltd.
    • Meridian Medical Technologies Inc.
    • Montreal, Inc.
    • Medivation, Inc.
    • Sugen LLC
    • Therachon Holding AG.
    • Jones Pharma Inc.
    • Trillium Therapeutics Inc.
UsernamePublicRestriction

Register